Artificial pancreas

Dexcom Signs Multi-Year Collaboration Agreement with the University of Virginia to Advance Type 1 and Type 2 Diabetes Research

Retrieved on: 
Thursday, September 24, 2020
Research, Medical devices, Diabetes, Clinical trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Medical technology, Medicine, Dexcom, Medical monitoring, Endocrine diseases, Continuous glucose monitor, Blood glucose monitoring, Diabetes, Blood tests, Artificial pancreas, Ambulatory glucose profile

DexCom, Inc. (NASDAQ:DXCM) today announced it has signed a five-year collaboration agreement with the University of Virginia to advance its research and development efforts on continuous glucose monitoring-based solutions.

Key Points: 
  • DexCom, Inc. (NASDAQ:DXCM) today announced it has signed a five-year collaboration agreement with the University of Virginia to advance its research and development efforts on continuous glucose monitoring-based solutions.
  • The University of Virginias Center for Diabetes Technology will spearhead the research efforts, led by Drs.
  • Dexcom and the University of Virginia have a long history of research and clinical collaboration, including the recent International Diabetes Closed Loop trial (iDCL).
  • The University of Virginia has become one of the worlds leading research institutes for diabetes technology, said Jim Ryan, president of the University of Virginia.

Global Diabetic Care Devices Market

Retrieved on: 
Monday, September 21, 2020
Medicine, Branches of biology, Medical technology, Medical monitoring, Continuous glucose monitor, Blood glucose monitoring, Glucose meter, Glucose test, Glucose, BD, Artificial pancreas, Ambulatory glucose profile

The global diabetes monitoring devices market generally consists of the following devices: self-glucose monitoring devices, blood glucose meter devices, blood glucose test strips, lancets and lancet devices, continuous glucose monitoring devices, transmitters and receivers.

Key Points: 
  • The global diabetes monitoring devices market generally consists of the following devices: self-glucose monitoring devices, blood glucose meter devices, blood glucose test strips, lancets and lancet devices, continuous glucose monitoring devices, transmitters and receivers.
  • The scope of the report includes an overview of the global market for diabetes monitoring devices and analyses of global market trends, using 2019 as the base year and forecasting 2020 through 2025 with compound annual growth rate (CAGR) projections.
  • The report concludes with detailed profiles of the major vendors in the global diabetes monitoring devices market.
  • - Estimation of the market size and analyses of global market trends, with data from 2019, estimates for 2020 and projections of compound annual growth rates (CAGRs) through 2025
    - Detailed analysis of the current market trends, market forecast, and drivers and restraints of the industry
    - Detailed description of Self-Monitoring of Blood Glucose (SMBG) and Continuous Glucose Monitoring (CGM) Systems and examination of market structure, and history of these devices
    - Identification of new opportunities, challenges, and technological changes within the industry and a look at the new products launches in the diabetes monitoring devices market
    - Company profiles of major players in the market including Abbott Laboratories, Becton, Dickinson and Co., Johnson & Johnson, Medtronic, Novo Nordisk A/S and Roche
    The global diabetes monitoring devices market was worth nearly $REDACTED billion in 2019.The market is expected to increase at a CAGR of REDACTED% during the forecast period of 2020 to 2025.

Arecor to Present at EASD 2020

Retrieved on: 
Monday, September 21, 2020
Clinical medicine, Medicine, Endocrine system, RTT, Peptide hormones, Recombinant proteins, Diabetes, Insulin, Artificial pancreas, Hyperglycemia

Abstract #55 is available online .

Key Points: 
  • Abstract #55 is available online .
  • Potential clinical benefits for avoiding hypo and hyperglycaemia need to be confirmed in further clinical studies.
  • This early evidence suggests that AT247 may facilitate a fully closed loop artificial pancreas, a potentially life changing treatment option for people living with diabetes."
  • Oral Presentation of Abstract #55:
    Phase I study investigating the PD, PK and safety of AT247 in comparison to insulin aspart and fast Insulin aspart

Medtronic Announces FDA Approval for MiniMed™ 770G Insulin Pump System with Smartphone Connectivity for People with Type 1 Diabetes

Retrieved on: 
Tuesday, September 1, 2020
Medicine, Clinical medicine, Medical technology, Medtronic, Insulin pump, Insulin, Minimed Paradigm, Artificial pancreas

This newest insulin pump system offers the company's most advanced SmartGuard technology, as featured in the MiniMed 670G system, with the added benefits of smartphone connectivity and an expanded age indication to children as young as 2.

Key Points: 
  • This newest insulin pump system offers the company's most advanced SmartGuard technology, as featured in the MiniMed 670G system, with the added benefits of smartphone connectivity and an expanded age indication to children as young as 2.
  • This connectivity also gives Medtronic the ability to provide upgrades to future technology via software updates which can further enhance security and device features.
  • "Being able to offer my patients an insulin pump system that provides safe, automated insulin delivery and smartphone connectivity is incredibly beneficial.
  • Medtronic will begin taking orders for the new MiniMed 770G system in the United States this week.

Global Automated Insulin Delivery Market (2020 to 2024) - Size & Forecast with Impact Analysis of COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Monday, August 31, 2020
Professional services, Consulting, Clinical medicine, Medicine, Endocrine system, RTT, Peptide hormones, Recombinant proteins, Diabetes management, Artificial pancreas, Insulin, Diabetes, Tandem Diabetes Care

Automated insulin delivery (AID) is also known as hybrid or full closed loop, artificial pancreas system (APS), looping, etc.

Key Points: 
  • Automated insulin delivery (AID) is also known as hybrid or full closed loop, artificial pancreas system (APS), looping, etc.
  • Automated insulin delivery (AID) is a method for managing diabetes but it is not same for every patient.
  • The global automated insulin delivery (AID) market has progressed promptly over the years and the market is further anticipated to escalate during the forecasted years 2020 to 2024.
  • Moreover, the market growth would also succeed by various market trends like rising adoption of wearable healthcare devices and novel product launches.

Continuous Subcutaneous Insulin Infusion Market Size Worth $7.3 Billion by 2027: Grand View Research, Inc.

Retrieved on: 
Thursday, July 30, 2020
Clinical medicine, Medicine, Endocrine system, Peptide hormones, Recombinant proteins, RTT, Insulin pump, Insulin, Diabetes, Artificial pancreas, Minimed Paradigm

SAN FRANCISCO, July 30, 2020 /PRNewswire/ -- The global continuous subcutaneous insulin infusion market size is expected to reach USD 7.3 billion by 2027, registering a CAGR of 10.3% over the forecast period, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, July 30, 2020 /PRNewswire/ -- The global continuous subcutaneous insulin infusion market size is expected to reach USD 7.3 billion by 2027, registering a CAGR of 10.3% over the forecast period, according to a new report by Grand View Research, Inc.
  • The key drivers of the market include increasing number of diabetes population coupled with technological advancement in the field of diabetes care.
  • They are leveraging technological advancement to improve market solutions like integrated insulin pumps, non-invasive insulin delivery systems, and closed-loop artificial pancreases.
  • Grand View Research has segmented the global continuous subcutaneous insulin infusion market on the basis of product type, patient type, end use, and region:
    Continuous Subcutaneous Insulin Infusion Product Type Outlook (Volume, Units; Revenue, USD Million, 2016 - 2027)

Continuous Subcutaneous Insulin Infusion Market Size Worth $7.3 Billion by 2027: Grand View Research, Inc.

Retrieved on: 
Thursday, July 30, 2020
Clinical medicine, Medicine, Endocrine system, Peptide hormones, Recombinant proteins, RTT, Insulin pump, Insulin, Diabetes, Artificial pancreas, Minimed Paradigm

SAN FRANCISCO, July 30, 2020 /PRNewswire/ -- The global continuous subcutaneous insulin infusion market size is expected to reach USD 7.3 billion by 2027, registering a CAGR of 10.3% over the forecast period, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, July 30, 2020 /PRNewswire/ -- The global continuous subcutaneous insulin infusion market size is expected to reach USD 7.3 billion by 2027, registering a CAGR of 10.3% over the forecast period, according to a new report by Grand View Research, Inc.
  • The key drivers of the market include increasing number of diabetes population coupled with technological advancement in the field of diabetes care.
  • They are leveraging technological advancement to improve market solutions like integrated insulin pumps, non-invasive insulin delivery systems, and closed-loop artificial pancreases.
  • Grand View Research has segmented the global continuous subcutaneous insulin infusion market on the basis of product type, patient type, end use, and region:
    Continuous Subcutaneous Insulin Infusion Product Type Outlook (Volume, Units; Revenue, USD Million, 2016 - 2027)

Continuous Glucose Monitoring Systems (CGMS) Market 2020-2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 22, 2020
Diabetes, Health, Medical devices, Medicine, Diabetes, Clinical medicine, Artificial pancreas, Biological engineering, Biomedical engineering, Prosthetics, Insulin pump, Blood glucose monitoring, Diabetes management, Continuous glucose monitor, Insulin

The continuous glucose monitoring systems (CGMS) market has emerged as a promising diabetes management tool for monitoring all types of diabetic patients.

Key Points: 
  • The continuous glucose monitoring systems (CGMS) market has emerged as a promising diabetes management tool for monitoring all types of diabetic patients.
  • Replacement/repeat sales of components such as sensors, drive the growth of the continuous glucose monitoring systems market.
  • FDA approval for the novel and innovative products such as artificial pancreas (dual-chambered investigational device that consists of a continuous glucose monitoring system, one insulin pump, and a control algorithm) would further drive the continuous glucose monitoring systems market trend.
  • Among components, sensors market contributed for the highest continuous glucose monitoring systems market share generating the revenue of $1,174.87 million in 2019 and will generate the largest market revenue of $6,087.22 million by 2027.

DreaMed’s Automated Insulin Delivery Technology Is Featured in Medtronic’s New System Bringing Its Vision of Helping People With Type 1 Diabetes to Life

Retrieved on: 
Wednesday, June 17, 2020
Software, Biotechnology, Internet, Health, Diabetes, Data management, Technology, Other Technology, Medical technology, Medicine, Artificial pancreas, Biological engineering, Biomedical engineering, Prosthetics, Clinical medicine, Medtronic, Diabetes management, Minimed Paradigm, International Diabetes Center at Park Nicollet

The successful project spawned the creation of DreaMed Diabetes and an agreement with Medtronic, leading to the implementation of the algorithm into the MiniMed 780G system.

Key Points: 
  • The successful project spawned the creation of DreaMed Diabetes and an agreement with Medtronic, leading to the implementation of the algorithm into the MiniMed 780G system.
  • The " MD-Logic Artificial Pancreas algorithm ," is an advanced hybrid closed loop system for controlling patient glucose levels.
  • The company was established in 2014 and commercialized its first product, MD-Logic artificial pancreas technology which was licensed to Medtronic Diabetes.
  • Ever since, DreaMed Diabetes has been vigorously working on the DreaMed Advisor portfolio, decision support tools in the diabetes management space.

Arecor announces Phase 1 of AT247 at ADA

Retrieved on: 
Monday, June 15, 2020
Medicine, RTT, Clinical medicine, Organ systems, Diabetes, Artificial pancreas, Biological engineering, Biomedical engineering, Prosthetics, Type 1 diabetes, EudraCT

AT247 also has the potential to enable a fully closed loop artificial pancreas, a potentially life changing treatment option for people living with diabetes."

Key Points: 
  • AT247 also has the potential to enable a fully closed loop artificial pancreas, a potentially life changing treatment option for people living with diabetes."
  • The double-blind, randomised, single dose, three-period cross over Phase I clinical study (EudraCT:2018-003934-34) compared the PK/PD profiles of AT247 to NovoRapidand Fiaspin 19 men with Type I diabetes.
  • Sarah Howell, Chief Executive Officer of Arecor, said:
    "The successful completion of our AT247 Phase I clinical study and selection for an oral presentation at ADA is an important landmark for Arecor.
  • In addition to the potential to improve post prandial blood glucose control, AT247 may play a critical role in advancing artificial pancreas systems.